Biomarkers and Clinical Research

Neurodegenerative Disease Biomarkers

Neurodegenerative disease biomarkers have emerged as crucial tools in the early diagnosis, monitoring, and treatment of disorders such as Alzheimer's, Parkinson's, and Huntington's diseases. Advances in biomarker research have led to the identification of various molecular and imaging markers that reflect the underlying pathological processes of these diseases. Biomarkers such as amyloid-beta and tau proteins in cerebrospinal fluid (CSF) and blood are pivotal in diagnosing Alzheimer's disease at preclinical stages. Similarly, alpha-synuclein and neurofilament light chain (NfL) have shown promise in detecting Parkinson's disease and other neurodegenerative conditions. These biomarkers not only aid in early diagnosis but also in tracking disease progression and response to therapies. Imaging biomarkers, including PET and MRI scans, provide non-invasive methods to visualize brain changes and monitor the effects of therapeutic interventions. The integration of these biomarkers in clinical practice enhances the precision of neurodegenerative disease management, offering hope for improved patient outcomes and the development of targeted therapies.